Skip to main content
editorial
. 2019 Dec;8(Suppl 4):S403–S406. doi: 10.21037/tlcr.2019.07.06

Table 1. Overall survival median by PD-L1 22C3 assay cutoffs.

Trial Overall survival (m, 95% CI) FU (m)
TPS ≥50% TPS 1–49% TPS <1%
KN-001 (tx naïve) 35.4 (20.3–63.5) 19.5 (10.7–26.3) 60.0
KN-024 30.0 (18.3–NR) 25.2
KN-042 20.0 (15.4–24.9) 13.4 (10.7–18.2) 12.8
KN-189 NR (>20.4) 21.8 (17.7–25.9) 17.2 (13.8–22.8) 18.7

CI, confidence interval; FU, median follow-up; KN, KEYNOTE; m, month(s); NR, not reached; PD-L1, programmed cell death ligand 1; TPS, tumor proportion score; tx, treatment.